Stock Report: () Report Updated: May 20, 2013 | Print This Page
Report Features:
(DUSA)
| Rating: | Volatility: |
| Total Grade: | Industry: |
| Competitors: |
Stock Analysis
Rating: Monthly View
| A |  |
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: |  no change |
|---|---|
| Last Week: | no change |
| Two Weeks Ago: | no change |
Company Profile
DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea. The company’s marketed products include Levulan Kerastick 20% Topical Solution with PDT, as well as the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. It also markets the BLU-U without Levulan PDT for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. The company was founded in 1991 and is headquartered in Wilmington, Massachusetts.
Recent News:
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio